Home » Kyowa Kirin’s Poteligeo Gains European Marketing Authorization
Kyowa Kirin’s Poteligeo Gains European Marketing Authorization
The European Commission granted marketing authorization for Kyowa Kirin’s Poteligeo (mogamulizumab), a treatment for adults with mycosis fungoides or Sézary syndrome who have undergone at least one prior systemic therapy.
The two cancers are the most common subtypes of cutaneous T-cell lymphoma, a rare form of non-Hodgkin’s lymphoma.
Poteligeo targets CC chemokine receptor 4-expressing T-cells in the patient’s blood and skin to manage symptoms. It is the first biologic agent targeting CCR4 to be approved in Europe.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May